ArticleDiscover oncology2026
Identification of RPL4 as a biomarker associated with disulfidptosis and arachidonic acid metabolism in breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveDisulfidptosis is a recently discovered mechanism of cell death caused by disulfide stress. Arachidonic acid metabolism (AAM) is one of the metabolic mechanisms of polyunsaturated fatty acids. However, few studies have explored the relationship between disulfidptosis and AAM and how together they affect breast cancer prognosis. The aim of this study was to establish a prognostic model of disulfidptosis and arachidonic acid metabolism in breast cancer and to investigate the potential mechanisms of disulfidptosis and arachidonic acid in breast cancer.
methodA comprehensive approach including single-cell sequencing analysis (scRNA-seq), weighted gene coexpression network analysis (WGNA), and transcriptome differential expression analysis was used to investigate this relationship. Cox regression and Lasso regression analysis were used to screen for arachidonic acid metabolism and disulfidptosis-related genes (AAMDRGs) in breast cancer. This study also comprehensively analyzed the risk score of AAMDRGs, as well as clinical features, tumor microenvironment, somatic mutations, immunotherapy, drug sensitivity, and molecular docking data.
resultSeven genes associated with disulfidptosis and AAM (ATP5F1B, RPL4, PRDX1, TCP1, CLDN7, GSTK1, PYCARD) were identified in this study. These genes were used to establish a prognostic model related to disulfidptosis and arachidonic acid in breast cancer. The model had excellent performance. Multi-indicator ROC analysis, DAC, and C-index all suggested that the model had high prediction accuracy. This study found that RPL4 is a key candidate gene that can serve as a biomarker for BC, with low expression associated with a poorer prognosis in cancer patients. In addition, this study found that axitinib has a predicted potential pharmacological binding relationship with RPL4 based on molecular docking analysis, which provides a basis for future preclinical and clinical validation studies.
conclusionThis machine learning-driven disulfidptosis-related and arachidonic acid metabolism-related model provides clinically actionable prognostic stratification, outperforming conventional gene signatures in precision oncology applications. RPL4 is a potential candidate biomarker associated with disulfidptosis and AAM-related pathways in breast cancer, and its potential as a therapeutic target requires further experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.